In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

Published Date: 15 Dec 2023

FDA is now reviewing the experimental medication revumenib for KMT2A-rearranged disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

2.

A new way to measure suicide risk?

3.

Taking vitamin D daily decreased cancer mortality, according to a study.

4.

Radiotherapy after mastectomy can be avoided, study finds

5.

In a recent study, Kencur ginger's anti-cancer properties were discovered.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot